Colorized structure of a prototype for a universal flu vaccine. The nanoparticle is a hybrid of a protein scaffold (blue) and eight influenza hemagglutinin proteins on the surface (yellow). The hemagglutinin was specifically engineered to display antibody binding sites common to all human influenza subtypes. The particle designed by Jeffrey Boyington (VRC) has been shown to be an effective immunogen in mice and ferrets (VRC). 3D structure of the particle was determined by cryo-electron microscopy by John Gallagher and Audray Harris (Laboratory of Infectious Diseases).
Credit
NIAID
Influenza Research at NIAID
NIAID is conducting and supporting research to find new and improved ways to diagnose, treat and prevent influenza infection.
Novel Coronavirus SARS-CoV-2
Credit
NIAID
New Data Sets on Access to Clinical Data
NIAID's cloud-based, secure data platform enables sharing of anonymous patient-level clinical data to help generate new knowledge to treat and prevent infectious diseases such as COVID-19.
Credit
NIAID
Antiviral Program for Pandemics
NIAID’s research program to develop safe and effective antivirals to combat SARS-CoV-2 will also build sustainable platforms for targeted drug discovery and development of antivirals against viruses with pandemic potential.
